학술논문
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration: Topical Acrizanib (LHA510) in Subjects With Neovascular AMD
Document Type
Article
Author
Source
In: American Journal of Ophthalmology . (American Journal of Ophthalmology, July 2022, 239:180-189)
Subject
Language
English
ISSN
18791891
00029394
00029394